Tag Archives: Agena Bioscience

April 2021—Agena Bioscience launched its MassArray SARS-CoV-2 Variant Panel (RUO) for the detection of key SARS-CoV-2 virus strains.

March 29, 2021—Agena Bioscience  launched its MassArray SARS-CoV-2 Variant Panel (RUO) for the detection of key SARS-CoV-2 virus strains.

December 2020—Agena Bioscience’s MassArray SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus has been granted emergency use authorization from the FDA.

Oct. 28, 2020—Agena Bioscience’s MassArray SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus has been granted emergency use authorization from the FDA.

December 2018—Agena Bioscience released its Chimeric ID Panel, designed to reduce the time and cost of performing chimerism analysis for bone marrow engraftment monitoring studies.

Aug. 24, 2018—Agena Bioscience announced it has entered into a collaboration with PerkinElmer, incorporating the LabChip GX Touch nucleic acid analyzer for quality assessment and quantitation of DNA in the upfront workflow of Agena’s MassArray system. The companies have focused on targeting ctDNA in oncology liquid biopsy, where the combined systems aim to support a low cost, highly robust, single-day ...

August 2018—Agena Bioscience has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics, an independent medical laboratories provider headquartered in Hangzhou, China.

May 2018—Agena Bioscience and Simcere Diagnostics signed a strategic partnership agreement to expand the use of Agena’s Mass­Array System for companion diagnostics and pharmacogenetic testing in China.

December 2017—Agena Bioscience announced a comparative study published in PLOS One (Sutton BC, et al. 2017;12[9]:e0183715) highlighting the use of its mass-spectrometry-based platform and iPlex HS chemistry for detection of somatic mutations in EGFR, KRAS, BRAF, and NRAS occurring in non-small cell lung cancer.

July 2017—Agena Bioscience introduced targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSeek Lung and Colon Panels enable the detection of mutations as low as 0.1 percent minor allele frequency from circulating tumor cells and circulating tumor DNA. The iPlex HS Lung and Colon Panels enable detection of mutations as low as one percent MAF from solid tumor tissue.

May 2017—Agena Bioscience announced a comparative study published in Scientific Reports highlighting the use of its mass-spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer.

June 2016—Agena Bioscience and Horizon Discovery Group announced a supply and distribution agreement to launch iPlex reference standards for performance verification of oncology assays used on the MassArray System.

January 2016—Agena Bioscience announced the planned commercial launch of its CE-IVD marked MassArray Dx Plus assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics.

June 2015—Agena Bioscience released the LungFusion Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. Using as little as 10 ng of complementary DNA template, the research-use-only, single-well panel identifies expressed translocations of known clinical relevance in formalin-fixed, paraffin-embedded and fresh frozen tissue samples.

April 2015—Agena Bioscience released the MassArray 24-Well System for mass spectrometry-based genetic analysis. The 24-well format is tailored to smaller clinical testing laboratories requiring modest sample throughput, reduced initial hardware costs, and reduced time to result.